Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

<p>Supp Tables</p>

Збережено в:

Бібліографічні деталі
Автор:	Renumathy Dhanasekaran (14962092) (author)
Інші автори:	Aida S. Hansen (14962095) (author), Jangho Park (14962098) (author), Lea Lemaitre (14962101) (author), Ian Lai (14962104) (author), Nia Adeniji (14962107) (author), Sibu Kuruvilla (14962110) (author), Akanksha Suresh (14962113) (author), Josephine Zhang (14962116) (author), Varsha Swamy (14962119) (author), Dean W. Felsher (14962122) (author)
Опубліковано:	2025
Предмети:	Cancer Cancer Biology Immuno-oncology Immunology Immune responses to cancer Tumor-associated macrophages Immunotherapy Checkpoint blockade Combination immunotherapy Oncogenes & Tumor Suppressors Oncogenes
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
за авторством: Xufeng Lu (14960724)
Опубліковано: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
за авторством: Francisco Exposito (16721403)
Опубліковано: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
за авторством: Francisco Exposito (16721403)
Опубліковано: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
за авторством: Francisco Exposito (16721403)
Опубліковано: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
за авторством: Francisco Exposito (16721403)
Опубліковано: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
за авторством: Francisco Exposito (16721403)
Опубліковано: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
за авторством: Xiaodong Shu (16721586)
Опубліковано: (2025)

Supp. Figure 1 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
за авторством: Renzo Perales-Linares (17314863)
Опубліковано: (2025)

Supp. Figure 2 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
за авторством: Renzo Perales-Linares (17314863)
Опубліковано: (2025)

Supp. Figure 3 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
за авторством: Renzo Perales-Linares (17314863)
Опубліковано: (2025)

Supp. Figure 4 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
за авторством: Renzo Perales-Linares (17314863)
Опубліковано: (2025)

Supp. Figure 5 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
за авторством: Renzo Perales-Linares (17314863)
Опубліковано: (2025)

Supp. Figure 6 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
за авторством: Renzo Perales-Linares (17314863)
Опубліковано: (2025)

Supplementary Table S3 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
за авторством: Shima Nakanishi (16336496)
Опубліковано: (2025)

Supplementary Table S4 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
за авторством: Shima Nakanishi (16336496)
Опубліковано: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
за авторством: Duygu Kuzuoglu-Ozturk (14960213)
Опубліковано: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
за авторством: Duygu Kuzuoglu-Ozturk (14960213)
Опубліковано: (2025)

Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
за авторством: Duygu Kuzuoglu-Ozturk (14960213)
Опубліковано: (2025)

Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
за авторством: Renzo Perales-Linares (17314863)
Опубліковано: (2025)

Supplementary Table S1-19 from Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations
за авторством: Yuxi Liu (15293121)
Опубліковано: (2025)

Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx
за авторством: Soyoung Kim (117362)
Опубліковано: (2025)

Supplementary Tables from The IGF2BP3–COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression
за авторством: Jing Tang (17314958)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_hkl671gik99ger5epdnq1h85kg